HiGenoMB®- HiMedia Proudly Announces CE-IVD Approval Received for Hi-PCR®COVID-FLU Multiplex Probe PCR Kit

HiGenoMB® Molecular Biology Division of HiMedia Laboratories Pvt. Ltd. the pioneers in Indian BioSciences manufacturing segment adds another feather in the cap with their newly CE/IVD approved Hi-PCR®COVID-FLU Multiplex Probe PCR Kit (MBPCR262).

Molecular Diagnostics based on real-time PCR is increasingly becoming the gold standard post COVID-19. Hi-PCR® COVID-FLU Multiplex Probe PCR Kit, is a multiplex PCR kit that can differentiate between COVID-19 and Flu using a single tube reaction. It is recommended for sensitive and specific detection of SARS-CoV-2 and Influenza virus in clinical samples. Targets include RdRp gene of SARS-CoV-2 virus, Influenza A virus (Swine flu 2009 H1N1 virus, seasonal H3N2 & seasonal H1N1), Influenza B virus and Internal control (IC).

Covid-19 pandemic has impacted millions of lives globally. The symptoms are similar to those of influenza, both being contagious respiratory illness. As the public's concern of contracting Covid-19 continued to rise, flu symptoms were frequently mistaken for those of Covid-19. Performing separate tests for detection of Covid-19 and Influenza can be time consuming, costly & a cumbersome affair. HiMedia’s MBPCR262 being a multiplex kit eliminates the need for separate tests thereby significantly reducing the time & resources.

Dr. Kavita Khadke, Director of HiMedia’s Molecular Biology Division (HiGenoMB®) says ‘’An early diagnostic tool that would help to differentiate between Flu and Covid-19 was the need of the hour. Time is of essence; this kit can give results in a short span, enabling rapid and appropriate detection that could help in early diagnosis & treatment. 

Please visit their website www.himedialabs.com for more details about HiGenoMB® products related COVID Molecular testing.

This press release is published by VOH team.*

Partners & Associate